Dexamethasone interferes with osteoblasts formation during osteogenesis through altering IGF-1-mediated angiogenesis

Area of Science:

• Skeletal Biology
• Developmental Biology
• Endocrinology

Background:

• Dexamethasone (Dex), a synthetic glucocorticoid, modulates osteoblast activity but its precise role in endochondral ossification remains unclear.
• Understanding Dex's impact on skeletal development is crucial for managing conditions involving bone growth.

Purpose of the Study:

• To investigate the effects of Dex on osteoblast formation, differentiation, and skeletal development.
• To elucidate the underlying mechanisms, including the role of insulin-like growth factor 1 (IGF-1) and angiogenesis.

Main Methods:

• In vivo studies using chick embryos and in vitro studies with preosteoblast cell cultures (MC3T3-E1).
• Chick chorioallantoic membrane (CAM) assays to assess angiogenesis and bone formation.
• Gene expression analysis and rescue experiments with IGF-1.

Main Results:

• Dex exposure shortened long bones in chick embryos and downregulated osteogenesis-related genes.
• Dex inhibited preosteoblast proliferation and viability, an effect reversed by IGF-1.
• Dex reduced angiogenesis and IGF-1 pathway signaling, which were rescued by IGF-1 treatment.

Conclusions:

• Dex-induced inhibition of IGF-1 signaling negatively impacts osteoblastogenesis and angiogenesis.
• This disruption ultimately leads to shortened long bones during skeletal development.